WEQUAL
8.11.2021 23:24:12 CET | Business Wire | Press release
Twenty-four women executives have been recognised by the WeQual Awards for their outstanding contribution to business from some of the biggest companies in the Europe, Middle East and Africa region. WeQual’s mission is to tackle the slow progress in appointing women to executive positions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211108006143/en/
Since its creation, more than 35% of the winners of previous WeQual Awards in the UK, EMEA, APAC and The Americas have already been promoted to the executive committees of major global companies.
The 24 WeQuals, all one level below Group ExCo or Group C-Suite leader, automatically become members of the WeQual Club. They join the 144 senior executives already enrolled. The winners in each category will be announced in January 2022.
The 24 WeQual Finalists for EMEA 2021:
Technology Category
- Cecile Bartenieff, COO of Global Banking & Investors Solutions and Global Head of Technology & Operations, Société Générale.
- Patricia Beau, Chief Technology Officer Lead / Partner For Consumer Healthcare, Sanofi.
- Miruna Senciuc, CEO, Romanian Branch, BNP Paribas Personal Finance.
Brand Category
- Mia Claselius, Vice President, Head of Communications, ABB Electrification, ABB Ltd.
- Noémie Ellezam, Group Chief Digital Strategy Officer, Société Générale.
- Anjana Srinivasan, Chief Operating Officer – HSBC Global Marketing, HSBC Holdings plc.
Transformation Category
- Naina Bhattacharya, Chief Information Security Officer, Danone.
- Christiane Lindenschmidt, Chief Digital and Data Officer, Markets and Securities Services, HSBC Holdings Plc.
- Chafika Chettaoui, Group Chief Data Officer, Suez.
Commercial Category
- Anne O'Leary, Chief Executive Officer, Vodafone Ireland, Vodafone Group Plc.
- Filipa Martins, Managing Director/CEO, Portugal, Edenred.
- Mieke De Schepper, Executive Vice President and Managing Director, Asia-Pacific, Amadeus IT Group.
Finance Category
- Anna Dimitrova, Chief Financial Officer and Strategy Director of Vodafone Germany
- Daria Dodonova, Chief Financial Officer, Magyar Telekom, Deutsche Telekom.
- Camila Japur, CFO Emerging Businesses, Ericsson.
Business Development Category
- Arancha Cordero, Chief Growth Officer Waters, Danone.
- Susan Uthayakumar, President, Sustainability Business Division, Schneider Electric.
- Bettina Möckel, Vice President Corporate Business Development, QIAGEN.
Procurement & Supply Chain Category
- Sigrid Brendel, Head of Global Procurement, CPO, Campari Group.
- Jessica Nordlinder, Chief Procurement Officer, Essity.
- Francesca Gamboni, Senior Vice President Global Supply Chain Groupe Stellantis, Stellantis.
People & Culture Category
- Audra Jenkins, Chief Diversity & Inclusion Officer, Randstad North America.
- Cecilia Hallengren, Senior Vice President, People and Culture, Volvo Group Trucks Technology, Volvo Group.
- Tina Mylon, SVP, Talent and Diversity, Schneider Electric.
Notes
Quotes available on request.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211108006143/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom